Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13070248 | 0.86 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10MMP8ALOX15 | |
| SCHEMBL803804 | 0.83 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10MMP8ALOX15 | |
| SCHEMBL13537856 | 0.83 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10MMP8ALOX15 | |
| SCHEMBL803891 | 0.83 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10MMP8ALOX15 | |
| SCHEMBL9620746 | 0.80 | ALDH1A1 (0.37) | ALDH1A1LMNAHSD17B10MMP8ALOX15 | |
| SCHEMBL11825489 | 0.79 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10MMP8ALOX15 | |
| SCHEMBL8652892 | 0.77 | ALDH1A1 (0.39) | ALDH1A1LMNAHSD17B10MMP8ALOX15 | |
| SCHEMBL19690677 | 0.77 | MMP8 (0.46) | ALDH1A1LMNAHSD17B10MMP8ALOX15 | |
| SCHEMBL31151745 | 0.77 | GAA (0.52) | ALDH1A1LMNAHSD17B10MMP8MGAM | |
| SCHEMBL765474 | 0.76 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10MMP8ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024707-A1 | INHIBITORS OF CDK2/4/6 KINASE | KINNATE BIOPHARMA INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-12-19 | — | — | US | disclosed |
| US-12110286-B2 | Benzimidazolone derived inhibitors of BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-10-08 | — | — | US | disclosed |
| CN-118561812-A | Benzimidazolone-derived BCL6 inhibitors | 癌症研究科技有限公司 | 2024-08-30 | — | — | CN | disclosed |
| EP-3630291-B9 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| EP-4374858-A2 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2024-05-29 | — | — | EP | disclosed |
| CN-111163839-B | Benzimidazolone-derived BCL6 inhibitors | 癌症研究科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-3630291-B1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-20210147382-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| CN-111163839-A | Benzimidazolone-derived BCL6 inhibitors | 癌症研究科技有限公司 | 2020-05-15 | — | — | CN | disclosed |
| EP-3630291-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215801-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147382-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | ALDH1A1 1654/4885LMNA 1022/4885HSD17B10 1333/4885 |
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | ALDH1A1 1654/4885LMNA 1022/4885HSD17B10 1333/4885 |
| US-12110286-B2 | Benzimidazolone derived inhibitors of BCL6 | BCL6, BCL6B, BCL3 | ALDH1A1 1654/4885LMNA 1022/4885HSD17B10 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.